Focused On-demand Library for Protein farnesyltransferase subunit beta

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P49356

UPID:

FNTB_HUMAN

Alternative names:

CAAX farnesyltransferase subunit beta; Ras proteins prenyltransferase subunit beta

Alternative UPACC:

P49356; B2RDX6; B4E1A0

Background:

Protein farnesyltransferase subunit beta, also known as CAAX farnesyltransferase subunit beta or Ras proteins prenyltransferase subunit beta, plays a pivotal role in the post-translational modification of proteins. It catalyzes the transfer of a farnesyl moiety from farnesyl diphosphate to a cysteine residue near the C-terminus of target proteins, a process crucial for their proper function and localization.

Therapeutic significance:

Understanding the role of Protein farnesyltransferase subunit beta could open doors to potential therapeutic strategies. Its involvement in the modification of proteins essential for cell signaling and growth positions it as a key target in the development of treatments for diseases where these processes are dysregulated.